Journal of Biomolecular Structure and Dynamics · 2024 · 13 citations · 26 references
Life SciencesBioinformaticsOncologyDrug DiscoveryGene ExpressionMolecular OncologyEnzyme FunctionEnzyme InhibitionProteolytic EnzymesTherapeutic EnzymesEnzymesGlioblastoma Drug TherapyHistone DeacetylasesInhibitor ScreeningMolecular Docking AnalysisPeptidase ActivityRepurposing Of Approved DrugsTherapeutic Enzyme Discovery
Despite considerable improvement in therapy and diagnosis, brain tumors remain a global public health concern. Among all brain tumors, 80% are due to Glioblastoma. The average survival rate of a patient once diagnosed with glioblastoma is 15 months. Lately, the role of peptidase enzymes, especially Neprilysin, a neutral endopeptidase, is gaining attention for its role in tumor growth regulation. Neprilysin expressions are positively correlated with several tumors including GBM and reduced expression of NEP protein is associated with the pathogenesis of multiple tumors. One of the main reasons for NEP protein downregulation is the action of Histone deacetylase (HDAC) enzymes, especially HDAC1. Additionally, studies have reported that increased levels of HDAC1 are responsible for downregulating NEP gene expression. Hence, HDAC1 inhibition can be a good target to elevate NEP levels, which can be a good therapeutic approach to GBM. This study utilizes the computational drug repurposing tool, Schrodinger Maestro to identify HDAC1 inhibitors from the ZINC15 database.1379 FDA-approved drugs from the ZINC15 database were screened through molecular docking. Based on docking score and ligand-protein interaction, the top ten molecules were selected which were then subjected to binding energy calculation and molecular dynamics (MD) simulations. The three most active drugs from the MD simulations- ZINC22010649 (Panobinostat), ZINC4392649 (Tasimelteon) and ZINC1673 (Melphalan), were tested on C6 and U87 MG glioblastoma cells for cytotoxicity and HDAC1 protein levels using western blot analysis. Among the three drugs, Panobinostat exhibited potent cytotoxic action and showed a significant reduction in the HDAC1 protein levels.
26
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai, Kanyawim Kirtikara · Nature Protocols · 2006 · 3.7K citations
Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates
Christopher J. Millard, Peter J. Watson, Ivana Celardo et al. · Molecular Cell · 2013 · 397 citations · Full text
Nikolai D. Belyaev, Katherine A. B. Kellett, Caroline S. Beckett et al. · Journal of Biological Chemistry · 2010 · 208 citations · Full text
Goverdhan Lanka, Darakhshan Begum, Suvankar Banerjee et al. · Computers in Biology and Medicine · 2023 · 100 citations